{"pmid":32360285,"pmcid":"PMC7189845","title":"Type I IFN immunoprofiling in COVID-19 patients.","text":["Type I IFN immunoprofiling in COVID-19 patients.","COVID patients in ICU present a high mortality rate and immunoprofiling reveals heterogeneous IFN-alpha2 production with about 20% of critically-ill patients unable to produce IFN-alpha2, highlighting the immune response heterogeneity and opening avenues for targeted therapies.","J Allergy Clin Immunol","Trouillet-Assant, Sophie","Viel, Sebastien","Gaymard, Alexandre","Pons, Sylvie","Richard, Jean-Christophe","Perret, Magali","Villard, Marine","Brengel-Pesce, Karen","Lina, Bruno","Mezidi, Mehdi","Bitker, Laurent","Belot, Alexandre","32360285"],"abstract":["COVID patients in ICU present a high mortality rate and immunoprofiling reveals heterogeneous IFN-alpha2 production with about 20% of critically-ill patients unable to produce IFN-alpha2, highlighting the immune response heterogeneity and opening avenues for targeted therapies."],"journal":"J Allergy Clin Immunol","authors":["Trouillet-Assant, Sophie","Viel, Sebastien","Gaymard, Alexandre","Pons, Sylvie","Richard, Jean-Christophe","Perret, Magali","Villard, Marine","Brengel-Pesce, Karen","Lina, Bruno","Mezidi, Mehdi","Bitker, Laurent","Belot, Alexandre"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360285","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jaci.2020.04.029","keywords":["covid-19","intensive care unit","sars-cov2 virus","type i interferon","innate immunity","viral infection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495935053824,"score":9.490897,"similar":[{"pmid":32364527,"title":"Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.","text":["Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.","Currently, we are on a global pandemic of Coronavirus disease-2019 (COVID-19) which causes fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) that may ultimately lead to the death of the infected. Current researches on COVID-19 continue to highlight the necessity for further understanding the virus-host synergies. In this study, we have highlighted the key cytokines induced by coronavirus infections. We have demonstrated that genes coding interleukins (Il-1alpha, Il-1beta, Il-6, Il-10), chemokine (Ccl2, Ccl3, Ccl5, Ccl10), and interferon (Ifn-alpha2, Ifn-beta1, Ifn2) upsurge significantly which in line with the elevated infiltration of T cells, NK cells and monocytes in SARS-Cov treated group at 24 hours. Also, interleukins (IL-6, IL-23alpha, IL-10, IL-7, IL-1alpha, IL-1beta) and interferon (IFN-alpha2, IFN2, IFN-gamma) have increased dramatically in MERS-Cov at 24 hours. A similar cytokine profile showed the cytokine storm served a critical role in the infection process. Subsequent investigation of 463 patients with COVID-19 disease revealed the decreased amount of total lymphocytes, CD3+, CD4+, and CD8+ T lymphocytes in the severe type patients which indicated COVID-19 can impose hard blows on human lymphocyte resulting in lethal pneumonia. Thus, taking control of changes in immune factors could be critical in the treatment of COVID-19.","Aging (Albany NY)","Yao, Zhixian","Zheng, Zhong","Wu, Ke","Junhua, Zheng","32364527"],"abstract":["Currently, we are on a global pandemic of Coronavirus disease-2019 (COVID-19) which causes fever, dry cough, fatigue and acute respiratory distress syndrome (ARDS) that may ultimately lead to the death of the infected. Current researches on COVID-19 continue to highlight the necessity for further understanding the virus-host synergies. In this study, we have highlighted the key cytokines induced by coronavirus infections. We have demonstrated that genes coding interleukins (Il-1alpha, Il-1beta, Il-6, Il-10), chemokine (Ccl2, Ccl3, Ccl5, Ccl10), and interferon (Ifn-alpha2, Ifn-beta1, Ifn2) upsurge significantly which in line with the elevated infiltration of T cells, NK cells and monocytes in SARS-Cov treated group at 24 hours. Also, interleukins (IL-6, IL-23alpha, IL-10, IL-7, IL-1alpha, IL-1beta) and interferon (IFN-alpha2, IFN2, IFN-gamma) have increased dramatically in MERS-Cov at 24 hours. A similar cytokine profile showed the cytokine storm served a critical role in the infection process. Subsequent investigation of 463 patients with COVID-19 disease revealed the decreased amount of total lymphocytes, CD3+, CD4+, and CD8+ T lymphocytes in the severe type patients which indicated COVID-19 can impose hard blows on human lymphocyte resulting in lethal pneumonia. Thus, taking control of changes in immune factors could be critical in the treatment of COVID-19."],"journal":"Aging (Albany NY)","authors":["Yao, Zhixian","Zheng, Zhong","Wu, Ke","Junhua, Zheng"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32364527","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.18632/aging.103101","keywords":["covid-19","sars-cov-2","cytokine storm"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495984336897,"score":236.92566},{"pmid":32403318,"title":"Porcine Epidemic Diarrhea Virus and the Host Innate Immune Response.","text":["Porcine Epidemic Diarrhea Virus and the Host Innate Immune Response.","Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus (CoV), is the causative agent of porcine epidemic diarrhea (PED). PED causes lethal watery diarrhea in piglets, which has led to substantial economic losses in many countries and is a great threat to the global swine industry. Interferons (IFNs) are major cytokines involved in host innate immune defense, which induce the expression of a broad range of antiviral effectors that help host to control and antagonize viral infections. PEDV infection does not elicit a robust IFN response, and some of the mechanisms used by the virus to counteract the host innate immune response have been unraveled. PEDV evades the host innate immune response by two main strategies including: (1) encoding IFN antagonists to disrupt innate immune pathway, and (2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provides insights for the better understanding of PEDV-host interactions and developing effective vaccines and antivirals against CoVs.","Pathogens","Li, Shasha","Yang, Jinping","Zhu, Zixiang","Zheng, Haixue","32403318"],"abstract":["Porcine epidemic diarrhea virus (PEDV), a swine enteropathogenic coronavirus (CoV), is the causative agent of porcine epidemic diarrhea (PED). PED causes lethal watery diarrhea in piglets, which has led to substantial economic losses in many countries and is a great threat to the global swine industry. Interferons (IFNs) are major cytokines involved in host innate immune defense, which induce the expression of a broad range of antiviral effectors that help host to control and antagonize viral infections. PEDV infection does not elicit a robust IFN response, and some of the mechanisms used by the virus to counteract the host innate immune response have been unraveled. PEDV evades the host innate immune response by two main strategies including: (1) encoding IFN antagonists to disrupt innate immune pathway, and (2) hiding its viral RNA to avoid the exposure of viral RNA to immune sensors. This review highlights the immune evasion mechanisms employed by PEDV, which provides insights for the better understanding of PEDV-host interactions and developing effective vaccines and antivirals against CoVs."],"journal":"Pathogens","authors":["Li, Shasha","Yang, Jinping","Zhu, Zixiang","Zheng, Haixue"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32403318","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/pathogens9050367","keywords":["coronavirus","immune evasion","innate immunity","porcine epidemic diarrhea virus","type i ifn"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666802845642391552,"score":154.1501},{"pmid":32324595,"title":"The laboratory tests and host immunity of COVID-19 patients with different severity of illness.","text":["The laboratory tests and host immunity of COVID-19 patients with different severity of illness.","BACKGROUND: The Coronavirus Disease-2019 (COVID-19), infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak in China. The host immunity of COVID-19 patients is unknown. METHODS: The routine laboratory tests and host immunity in COVID-19 patients with different severity of illness were compared after patient admission. RESULTS: A total of 65 SARS-CoV-2-positive patients were classified as mild (n=30), severe (n=20), and extremely severe (n=15) illness. Many routine laboratory tests such as ferritin, lactate dehydrogenase and D-dimer were increased in severe and extremely severe patients. The absolute numbers of CD4+ T cells, CD8+ T cells and B cells were all gradually decreased with increased severity of illness. The activation markers such as HLA-DR and CD45RO expressed on CD4+ and CD8+ T cells were increased in severe and extremely severe patients compared with mild patients. The co-stimulatory molecule CD28 had opposite results. The percentage of natural regulatory T cells was decreased in extremely severe patients. The percentage of IFN-gamma producing CD8+ T cells was increased in both severe and extremely severe patients compared with mild patients. The percentage of IFN-gamma producing CD4+ T cells was increased in extremely severe patients. The IL-2R, IL-6, and IL-10 were all increased in extremely severe patients. The activation of DC and B cells was decreased in extremely severe patients. CONCLUSIONS: The number and function of T cells are inconsistent in COVID-19 patients. The hyperfunction of CD4+ and CD8+ T cells is associated with the pathogenesis of extremely severe SARS-CoV-2 infection.","JCI Insight","Wang, Feng","Hou, Hongyan","Luo, Ying","Tang, Guoxing","Wu, Shiji","Huang, Min","Liu, Weiyong","Zhu, Yaowu","Lin, Qun","Mao, Liyan","Fang, Minghao","Zhang, Huilan","Sun, Ziyong","32324595"],"abstract":["BACKGROUND: The Coronavirus Disease-2019 (COVID-19), infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused a severe outbreak in China. The host immunity of COVID-19 patients is unknown. METHODS: The routine laboratory tests and host immunity in COVID-19 patients with different severity of illness were compared after patient admission. RESULTS: A total of 65 SARS-CoV-2-positive patients were classified as mild (n=30), severe (n=20), and extremely severe (n=15) illness. Many routine laboratory tests such as ferritin, lactate dehydrogenase and D-dimer were increased in severe and extremely severe patients. The absolute numbers of CD4+ T cells, CD8+ T cells and B cells were all gradually decreased with increased severity of illness. The activation markers such as HLA-DR and CD45RO expressed on CD4+ and CD8+ T cells were increased in severe and extremely severe patients compared with mild patients. The co-stimulatory molecule CD28 had opposite results. The percentage of natural regulatory T cells was decreased in extremely severe patients. The percentage of IFN-gamma producing CD8+ T cells was increased in both severe and extremely severe patients compared with mild patients. The percentage of IFN-gamma producing CD4+ T cells was increased in extremely severe patients. The IL-2R, IL-6, and IL-10 were all increased in extremely severe patients. The activation of DC and B cells was decreased in extremely severe patients. CONCLUSIONS: The number and function of T cells are inconsistent in COVID-19 patients. The hyperfunction of CD4+ and CD8+ T cells is associated with the pathogenesis of extremely severe SARS-CoV-2 infection."],"journal":"JCI Insight","authors":["Wang, Feng","Hou, Hongyan","Luo, Ying","Tang, Guoxing","Wu, Shiji","Huang, Min","Liu, Weiyong","Zhu, Yaowu","Lin, Qun","Mao, Liyan","Fang, Minghao","Zhang, Huilan","Sun, Ziyong"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324595","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1172/jci.insight.137799","keywords":["adaptive immunity","cellular immune response","immunology","infectious disease","innate immunity"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138493807493120,"score":142.60413},{"pmid":32333818,"title":"COVID-19: lambda interferon against viral load and hyperinflammation.","text":["COVID-19: lambda interferon against viral load and hyperinflammation.","Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183,470 deaths [JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9 ecf6]. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNlambda), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNlambda in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNlambda induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNlambda and potential safety considerations. We conclude that IFNlambda constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS).","EMBO Mol Med","Andreakos, Evangelos","Tsiodras, Sotirios","32333818"],"abstract":["Coronavirus Disease 2019 (COVID-19), triggered by the betacoronavirus SARS-CoV-2, has become one of the worst pandemics of our time that has already caused more than 183,470 deaths [JHU data-23/04/2020, https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9 ecf6]. Effective therapeutic approaches are urgently needed to reduce the spread of the virus and its death toll. Here, we assess the possibility of using interferon lambda (IFNlambda), a third type of interferon sharing low homology with type I IFNs and IL-10, for treating COVID-19 patients. We discuss the unique role of IFNlambda in fine-tuning antiviral immunity in the respiratory tract to achieve optimal protection and minimal host damage and review early evidence that SARS-CoV-2 may impair IFNlambda induction, leading to a delayed type I IFN-dominated response that triggers hyperinflammation and severe disease. We also consider the potential windows of opportunity for therapeutic intervention with IFNlambda and potential safety considerations. We conclude that IFNlambda constitutes a promising therapeutic agent for reducing viral presence and hyperinflammation in a single shot to prevent the devastating consequences of COVID-19 such as pneumonia and acute respiratory distress syndrome (ARDS)."],"journal":"EMBO Mol Med","authors":["Andreakos, Evangelos","Tsiodras, Sotirios"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333818","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.15252/emmm.202012465","keywords":["covid-19","cytokine storm","hyperinflammation","interferon","viral infection"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493945905152,"score":128.7362},{"pmid":32445881,"title":"Arbidol/IFN-alpha2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study.","text":["Arbidol/IFN-alpha2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study.","The spread of COVID-19 is accelerating. At present, there is no specific antiviral drugs for COVID-19 outbreak. This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged >/=18 years) without ventilation were included. Combined group patients were given Arbidol and IFN-alpha2b, monotherapy group patients inhaled IFN-alpha2b for 10-14 days. Of 141 COVID-19 patients, baseline clinical and laboratory characteristics were similar between combined group and monotherapy group, that 30% of the patients leucocytes counts were below the normal range and 36.4% of the patients experienced lymphocytopenia. The duration of viral RNA of respiratory tract in the monotherapy group was not longer than that in the combined therapy group. There was no significant differences between two groups. The absorption of pneumonia in the combined group was faster than that in the monotherapy group. We inferred that Arbidol/IFN - 2b therapy can be used as an effective method to improve the COVID-19 pneumonia of mild patients, although it helpless with accelerating the virus clearance. These results should be verified in a larger prospective randomized environment.","Microbes Infect","Xu, Ping","Huang, Jianping","Fan, Zhao","Huang, Wendi","Qi, Minghua","Lin, Xuwen","Song, Weidong","Yi, Li","32445881"],"abstract":["The spread of COVID-19 is accelerating. At present, there is no specific antiviral drugs for COVID-19 outbreak. This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged >/=18 years) without ventilation were included. Combined group patients were given Arbidol and IFN-alpha2b, monotherapy group patients inhaled IFN-alpha2b for 10-14 days. Of 141 COVID-19 patients, baseline clinical and laboratory characteristics were similar between combined group and monotherapy group, that 30% of the patients leucocytes counts were below the normal range and 36.4% of the patients experienced lymphocytopenia. The duration of viral RNA of respiratory tract in the monotherapy group was not longer than that in the combined therapy group. There was no significant differences between two groups. The absorption of pneumonia in the combined group was faster than that in the monotherapy group. We inferred that Arbidol/IFN - 2b therapy can be used as an effective method to improve the COVID-19 pneumonia of mild patients, although it helpless with accelerating the virus clearance. These results should be verified in a larger prospective randomized environment."],"journal":"Microbes Infect","authors":["Xu, Ping","Huang, Jianping","Fan, Zhao","Huang, Wendi","Qi, Minghua","Lin, Xuwen","Song, Weidong","Yi, Li"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445881","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.micinf.2020.05.012","keywords":["2019-ncov","arbidol","covid-19","ifn-alpha2b","rna","pneumonia","treatment"],"locations":["Hubei","Guangdong"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1667600475793391616,"score":120.2245}]}